Biohaven Ltd. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Biohaven Ltd. (BHVN) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$56.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-10
- Biohaven Ltd. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $7.46M, a 65.47% decline year-over-year.
- Biohaven Ltd. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$64.41M, a 2415.38% decline year-over-year.
- Biohaven Ltd. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$12.79M.
- Biohaven Ltd. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$7.37M, a 252.58% decline year-over-year.
- Biohaven Ltd. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $4.21M, a 47.73% decline from fiscal 2024.
- Biohaven Ltd. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $8.06M.
- Biohaven Ltd. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$7.44M, a 209.30% decline from fiscal 2022.
- Biohaven Ltd. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $6.80M, a 30.72% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$56.96M 10-Q · filed 2026-08-10 | -$69.75M derived: sum of 3 quarters · filed 2026-08-10 | -$77.12M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | -$64.41M 10-Q · filed 2026-05-04 | -$77.21M derived: sum of 2 quarters · filed 2026-05-04 | -$84.58M derived: sum of 3 quarters · filed 2026-05-04 | -$62.98M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | -$12.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$20.16M derived: sum of 2 quarters · filed 2026-03-02 | $1.43M derived: sum of 3 quarters · filed 2026-08-10 | $4.21M 10-K · filed 2026-03-02 | ||
| 2025-09-30 | -$7.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $14.22M derived: sum of 2 quarters · filed 2026-08-10 | $17.00M 10-Q · filed 2025-11-10 | $4.37M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $21.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $24.38M 10-Q · filed 2026-08-10 | $11.74M derived: sum of 3 quarters · filed 2026-08-10 | $16.57M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $2.78M 10-Q · filed 2026-05-04 | -$9.85M derived: sum of 2 quarters · filed 2026-05-04 | -$5.02M derived: sum of 3 quarters · filed 2026-05-04 | $1.67M derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | -$12.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$7.80M derived: sum of 2 quarters · filed 2026-03-02 | -$1.12M derived: sum of 3 quarters · filed 2026-03-02 | $8.06M 10-K · filed 2026-03-02 | ||
| 2024-09-30 | $4.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $11.52M derived: sum of 2 quarters · filed 2025-11-10 | $20.69M 10-Q · filed 2025-11-10 | $7.16M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-06-30 | $6.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $15.86M 10-Q · filed 2025-08-11 | $2.33M derived: sum of 3 quarters · filed 2026-03-02 | $18.49M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-03-31 | $9.17M 10-Q · filed 2025-05-12 | -$4.35M derived: sum of 2 quarters · filed 2026-03-02 | $11.81M derived: sum of 3 quarters · filed 2026-03-02 | $16.02M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2023-12-31 | -$13.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.63M derived: sum of 2 quarters · filed 2026-03-02 | $6.85M derived: sum of 3 quarters · filed 2026-03-02 | -$7.44M 10-K · filed 2026-03-02 | ||
| 2023-09-30 | $16.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $20.38M derived: sum of 2 quarters · filed 2024-11-12 | $6.09M 10-Q · filed 2024-11-12 | $24.79M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-06-30 | $4.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$10.07M 10-Q · filed 2024-08-09 | $8.63M derived: sum of 3 quarters · filed 2025-03-03 | -$27.52M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-03-31 | -$14.29M 10-Q · filed 2024-05-09 | $4.41M derived: sum of 2 quarters · filed 2025-03-03 | -$31.73M derived: sum of 3 quarters · filed 2025-03-03 | $1.39M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $18.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$17.45M derived: sum of 2 quarters · filed 2025-03-03 | $15.67M derived: sum of 3 quarters · filed 2025-03-03 | $6.80M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | -$36.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$3.03M derived: sum of 2 quarters · filed 2023-11-14 | -$11.89M 10-Q · filed 2023-11-14 | -$13.46M 10-Q · filed 2022-11-09 | -$2.92M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $33.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $24.25M 10-Q · filed 2023-07-31 | $33.23M derived: sum of 3 quarters · filed 2024-02-29 | |||
| 2022-03-31 | -$8.87M 10-Q · filed 2023-05-12 | $107.00K derived: sum of 2 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | $8.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $9.82M 10-K · filed 2024-02-29 | $7.88M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $845.00K 10-Q · filed 2022-11-09 | |||||
| 2020-12-31 | $14.86M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |